36729-22-3

Usage

Uses

Used in the Fragrance Industry:
2,3-dimethyl-1H-indol-5-ol is used as a fragrance ingredient for its floral scent, adding a pleasant aroma to various products such as perfumes, cosmetics, and other scented goods.
Used in the Food and Beverage Industry:
Tryptophol is used as a natural flavoring agent in the food and beverage industry, enhancing the taste and aroma of products, particularly alcoholic beverages like beer and wine, where it contributes to their characteristic flavors.
Used in Pharmaceutical Applications:
2,3-dimethyl-1H-indol-5-ol is used as a research compound for its potential therapeutic applications, including the regulation of sleep and circadian rhythms, as well as its sedative and hypnotic effects, which may be beneficial in the development of treatments for sleep disorders and related conditions.
Used in Sleep and Circadian Rhythm Regulation Research:
Tryptophol is used as a subject of scientific research to explore its role in sleep regulation and the influence on circadian rhythms, potentially leading to advancements in understanding and managing sleep-related disorders.

Upstream product

• 105902-55-4 5-ethoxy-2,3-dimethyl-indole 
• 828-94-4 2,3-dimethyl-5-methoxyindole 
• 19501-58-7 4-methoxyphenylhydrazine hydrochloride 

Relevant academic research and scientific papers

FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS

The present invention relates to anti-tropomyosin compounds, processes for their preparation, and methods for treating or preventing a disease or disorder, such as a proliferative disease (preferably cancer), using compounds of the invention.

FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS

The present invention relates broadly to functionalised and substituted indoles, the preparation thereof and their use in the treatment of proliferative diseases such as cancer.

QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS

The invention relates to the use of compounds of the formula I: wherein ring C is an 8, 9, 10, 12 or 13-membered bicyclic or tricyclic moiety which optionally may contain 1-3 heteroatoms selected independently from O, N and S; Z is -O-, -NH-, -S-, -CH2- or a direct bond; n is 0-5; m is 0-3; R represents hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C1-3alkyl, C1-3alkoxy, C1-3alkylsulphanyl, -NRR (wherein R and R, which may be the same or different, each represents hydrogen or C1-3alkyl), or RX- (wherein X and R are as defined herein; R represents hydrogen, oxo, halogeno, hydroxy, C1-4alkoxy, C1-4alkyl, C1-4alkoxymethyl, C1-4alkanoyl, C1-4haloalkyl, cyano, amino, C2-5alkenyl, C2-5alkynyl, C1-3alkanoyloxy, nitro, C1-4alkanoylamino, C1-4alkoxycarbonyl, C1-4alkylsulphanyl, C1-4alkylsulphinyl, C1-4alkylsulphonyl, carbamoyl, N-C1-4alkylcarbamoyl, N,N-di(C1-4alkyl)carbamoyl, aminosulphonyl, N-C1-4alkylaminosulphonyl, N,N-di(C1-4alkyl)aminosulphonyl, N-(C1-4alkylsulphonyl)amino, N-(C1-4alkylsulphonyl)-N-(C1-4alkyl)amino, N,N-di(C1-4alkylsulphonyl)amino, a C3-7alkylene chain joined to two ring C carbon atoms, C1-4alkanoylaminoC1-4alkyl, carboxy or a group RX (wherein X and R are as defined herein); and salts thereof, in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals, processes for the preparation of such compounds, pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient and compounds of formula I. The compounds of formula I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.